MEDICAL MARIJUANA INC - MJNA STOCK NEWS

Medical Marijuana, Inc. (MJNA) announced that its subsidiary, Kannaway® Japan, achieved its highest revenue month in November 2021. The company credits significant growth in Japan, anticipating the global CBD oil market to reach $5.3 billion by 2025, with Asia-Pacific as a key growth area. Executive statements highlight strong consumer interest and education efforts around CBD products. Kannaway® aims to lead the CBD market in Japan and globally.

Medical Marijuana, Inc. (OTC: MJNA) announced the appointment of Jose Miguel Gutierrez Vazquez as Sales Director for its subsidiary, Kannaway®, in Mexico. With over 15 years of experience in marketing and sales, Vazquez is expected to enhance the company's operations in a market projected to grow significantly, with CBD market value forecasted to surpass $60 million by 2024. CEO Blake Schroeder emphasized the importance of Mexico as a growth area for the company, highlighting previous successes in securing legal import permits.

Medical Marijuana, Inc. (MJNA) announced that CEO Blake Schroeder participated in a Seeking Alpha podcast episode titled “Making Sense Of Cannabis Stocks” on November 17, 2021. The discussion highlighted the challenges and opportunities in the cannabis industry, along with potential legislative impacts for significant growth. Schroeder emphasized the company’s first-mover advantages in the market and its achievements, including being the first to obtain import permits for CBD products in Latin America. The U.S. cannabis market is projected to reach $51 billion by 2025, with a global market size of $70.6 billion by 2028.

Medical Marijuana, Inc. (MJNA) announced that its subsidiary, Kannaway®, has expanded operations into South Africa by appointing Duduzile Mathole as Country Manager. This expansion comes as South Africa's CBD market, valued at approximately $1.9 billion, continues to grow since the country de-scheduled CBD in 2020. Mathole's extensive experience in direct selling and knowledge of regional cannabis regulations are expected to aid in establishing and growing the company's presence in the region.

Medical Marijuana, Inc. (MJNA) announced its third-quarter financial results for 2021, reporting $9.2 million in net revenue and a net ordinary loss of $640,000. Gross profit for the quarter stood at $6.7 million, with a 47% increase in cash balance compared to the same period last year. Notably, long-term debt saw a 54% decrease. The company’s subsidiaries achieved record revenues, and it expanded operations into Hong Kong, aiming to be a global cannabis leader.

Medical Marijuana, Inc. (OTC: MJNA) has announced the promotion of Peter Dale, previously General Manager for Japan, to Global Chief Sales Officer. In his new role, Dale will oversee global sales and business development efforts, aiming to enhance productivity and strengthen relationships with entrepreneurs and customers. Dale has over 30 years of leadership experience in the industry and has significantly contributed to the company's growth in Asia. This strategic leadership change is expected to bolster Kannaway®'s sales operations and support ongoing growth initiatives.

Medical Marijuana, Inc. (OTC: MJNA) announced a significant legal victory for its subsidiary, Kannaway®, in Finland, affirming the legality of CBD oil importation. The Finnish Supreme Administrative Court ruled that Kannaway® Pure Gold is not classified as a medicinal product, setting a precedent for the industry in Europe. This ruling is expected to benefit the European hemp market and solidifies Kannaway®'s position as a leader in the CBD sector. CEO Blake Schroeder highlighted the ruling as a step towards becoming a global cannabis entity.